Oasmia Pharmaceutical AB Insiders
OASMYDelisted Stock | USD 0.06 0.00 0.00% |
Oasmia Pharmaceutical employs about 17 people. The company is managed by 10 executives with a total tenure of roughly 40 years, averaging almost 4.0 years of service per executive, having 1.7 employees per reported executive. Break down of Oasmia Pharmaceutical's management performance can provide insight into the company performance.
Kai Wilkinson Insider Chief Officer |
Urban Ekelund Insider IR Mang |
Oasmia |
Oasmia Pharmaceutical Management Team Effectiveness
The company has return on total asset (ROA) of (0.0875) % which means that it has lost $0.0875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2542) %, meaning that it generated substantial loss on money invested by shareholders. Oasmia Pharmaceutical's management efficiency ratios could be used to measure how well Oasmia Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Oasmia Pharmaceutical Workforce Comparison
Oasmia Pharmaceutical AB is considered to be number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is now estimated at about 258,086. Oasmia Pharmaceutical adds roughly 17.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
Oasmia Pharmaceutical Notable Stakeholders
An Oasmia Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oasmia Pharmaceutical often face trade-offs trying to please all of them. Oasmia Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oasmia Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kai Wilkinson | Chief Officer | Profile | |
Urban Ekelund | IR Mang | Profile | |
Henrik Rnnberg | Chief Health | Profile | |
John Cosby | Head Affairs | Profile | |
Robert Maiorana | Head CFO | Profile | |
Dzianis Babrou | Head Devel | Profile | |
Christer MD | Acting Officer | Profile | |
Reinhard Koenig | Chief Officer | Profile | |
Johanna Rostin | Head Affairs | Profile | |
Maria Hagberg | Head Affairs | Profile |
About Oasmia Pharmaceutical Management Performance
The success or failure of an entity such as Oasmia Pharmaceutical often depends on how effective the management is. Oasmia Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oasmia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oasmia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden. Vivesto Ab operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 17 people.
Please note, the imprecision that can be found in Oasmia Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oasmia Pharmaceutical AB. Check Oasmia Pharmaceutical's Beneish M Score to see the likelihood of Oasmia Pharmaceutical's management manipulating its earnings.
Oasmia Pharmaceutical Workforce Analysis
Traditionally, organizations such as Oasmia Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oasmia Pharmaceutical within its industry.Oasmia Pharmaceutical Manpower Efficiency
Return on Oasmia Pharmaceutical Manpower
Revenue Per Employee | 1.5M | |
Revenue Per Executive | 2.6M | |
Net Loss Per Employee | 7.8M | |
Net Loss Per Executive | 13.3M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Oasmia Pink Sheet
If you are still planning to invest in Oasmia Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oasmia Pharmaceutical's history and understand the potential risks before investing.
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |